APA (7th ed.) Citation

Helen Damerow, Xia Cheng, Valeska von Kiedrowski, Ralf Schirrmacher, Björn Wängler, Gert Fricker, & Carmen Wängler. (2022). Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? MDPI AG.

Chicago Style (17th ed.) Citation

Helen Damerow, Xia Cheng, Valeska von Kiedrowski, Ralf Schirrmacher, Björn Wängler, Gert Fricker, and Carmen Wängler. Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? MDPI AG, 2022.

MLA (9th ed.) Citation

Helen Damerow, et al. Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? MDPI AG, 2022.

Warning: These citations may not always be 100% accurate.